Peter Lindgren

Publications
CV
Public outreach and news

Articles

Article: BLOOD PRESSURE MONITORING. 2023;28(2):86-95

Real-world long-term effects on blood pressure and other cardiovascular risk factors for patients in digital therapeutics.

Willis M; Darwiche G; Carlsson M; Nilsson A; Wohlin J; Lindgren P
Article: VALUE IN HEALTH. 2023;26(3):328-335

The Allocation of the Economic Value of Second-Generation Antipsychotics Over the Product Life Cycle: The Case of Risperidone in Sweden and the United Kingdom.

Berdud M; Wallin-Bernhardsson N; Zamora B; Lindgren P; Towse A
Article: FRONTIERS IN MEDICINE. 2023;10:1119506

A global analysis of the value of precision medicine in oncology - The case of non-small cell lung cancer.

Hofmarcher T; Malmberg C; Lindgren P
Article: JOURNAL OF CANCER POLICY. 2022;34:100362

Systemic anti-cancer therapy patterns in advanced non-small cell lung cancer in Europe.

Hofmarcher T; Lindgren P; Wilking N
Article: PHARMACOECONOMICS. 2022;40(11):1095-1105

A Proposal of a Cost-Effectiveness Modeling Approach for Heart Failure Treatment Assessment: Considering the Short- and Long-Term Impact of Hospitalization on Event Rates.

Di Tanna GL; Angell B; Urbich M; Lindgren P; Gaziano TA; Globe G; Stollenwerk B
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2022;23(6):1059-1070

Value appropriation in hepatitis C.

Lindgren P; Löfvendahl S; Brådvik G; Weiland O; Jönsson B
Article: EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES. 2022;8(1):31-38

Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden.

Landmesser U; Lindgren P; Hagström E; van Hout B; Villa G; Pemberton-Ross P; Arellano J; Svensson ME; Sibartie M; Fonarow GC
Article: PLOS ONE. 2022;17(12):e0278369

Motivation 2 Quit (M2Q): A cluster randomized controlled trial evaluating the effectiveness of Tobacco Cessation on Prescription in Swedish primary healthcare.

Leppänen A; Lindgren P; Sundberg CJ; Petzold M; Tomson T
Article: NEUROLOGY AND THERAPY. 2021;10(2):919-940

Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer's Disease.

Herring WL; Gould IG; Fillit H; Lindgren P; Forrestal F; Thompson R; Pemberton-Ross P
Article: JOURNAL OF VIRAL HEPATITIS. 2021;28(1):142-146

Reduced work absenteeism in patients with hepatitis C treated with second-generation direct-acting antivirals.

Lindgren P; Löfvendahl S; Brådvik G; Weiland O
Article: DIABETOLOGIA. 2020;63(12):2582-2594

Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden.

Andersson E; Persson S; Hallén N; Ericsson Å; Thielke D; Lindgren P; Steen Carlsson K; Jendle J
Article: BRITISH JOURNAL OF SPORTS MEDICINE. 2020;54(21):1294-1299

A Swedish primary healthcare prevention programme focusing on promotion of physical activity and a healthy lifestyle reduced cardiovascular events and mortality: 22-year follow-up of 5761 study participants and a reference group.

Journath G; Hammar N; Vikström M; Linnersjö A; Walldius G; Krakau I; Lindgren P; de Faire U; Hellenius M-L
Article: BMC EMERGENCY MEDICINE. 2020;20(1):85

Healthcare pathways and resource use: mapping consequences of ambulance assessment for direct care with alternative healthcare providers.

Varg S; Vicente V; Castren M; Lindgren P; Rehnberg C
Article: DIABETES OBESITY & METABOLISM. 2020;22(9):1586-1597

Days absent from work as a result of complications associated with type 2 diabetes: Evidence from 20 years of linked national registry data in Sweden.

Persson S; Johansen P; Andersson E; Lindgren P; Thielke D; Thorsted BL; Jendle J; Steen Carlsson K
Article: NATURE REVIEWS UROLOGY. 2020;17(6):351-362

Introducing PIONEER: a project to harness big data in prostate cancer research.

Omar MI; Roobol MJ; Ribal MJ; Abbott T; Agapow P-M; Araujo S; Asiimwe A; Auffray C; Balaur I; Beyer K; Bernini C; Bjartell A; Briganti A; Butler-Ransohoff J-E; Campi R; Cavelaars M; De Meulder B; Devecseri Z; Voss MD; Dimitropoulos K; Evans-Axelsson S; Franks B; Fullwood L; Horgan D; Smith EJ; Kiran A; Kivinummi K; Lambrecht M; Lancet D; Lindgren P; MacLennan S; MacLennan S; Nogueira MM; Moen F; Moinat M; Papineni K; Reich C; Reiche K; Rogiers S; Sartini C; van Bochove K; van Diggelen F; Van Hemelrijck M; Van Poppel H; Zong J; N'Dow J; PIONEER Consortium
Article: BMJ OPEN. 2020;10(6):e032573

Time-driven activity-based costing for patients with multiple chronic conditions: a mixed-method study to cost care in a multidisciplinary and integrated care delivery centre at a university-affiliated tertiary teaching hospital in Stockholm, Sweden.

Keel G; Muhammad R; Savage C; Spaak J; Gonzalez I; Lindgren P; Guttmann C; Mazzocato P
Article: EUROPEAN JOURNAL OF CANCER. 2020;129:41-49

The cost of cancer in Europe 2018.

Hofmarcher T; Lindgren P; Wilking N; Jönsson B
Article: INTERNATIONAL JOURNAL OF HEALTH PLANNING AND MANAGEMENT. 2019;34(4):1439-1455

Exploring staff experience of economic efficiency requirements in health care: A mixed method study.

Korlén S; Amer-Wåhlin I; Lindgren P; von Thiele Schwarz U
Article: DISABILITY AND REHABILITATION. 2019;41(8):966-973

Psychometric properties of the Zarit Caregiver Burden Interview administered to caregivers to patients with Duchenne muscular dystrophy: a Rasch analysis.

Landfeldt E; Mayhew A; Straub V; Bushby K; Lochmüller H; Lindgren P
Article: APPLIED HEALTH ECONOMICS AND HEALTH POLICY. 2019;17(1):15-24

Standardized Questionnaire for the Measurement, Valuation, and Estimation of Costs of Informal Care Based on the Opportunity Cost and Proxy Good Method.

Landfeldt E; Zethraeus N; Lindgren P
Article: JOURNAL OF MULTIDISCIPLINARY HEALTHCARE. 2019;12:1075-1083

Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.

Rafiq M; Keel G; Mazzocato P; Spaak J; Guttmann C; Lindgren P; Savage C
Article: BMC HEALTH SERVICES RESEARCH. 2018;18(1):963

The development and validation of a scale to explore staff experience of governance of economic efficiency and quality (GOV-EQ) of health care.

Korlén S; Richter A; Amer-Wåhlin I; Lindgren P; von Thiele Schwarz U
Article: AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV. 2018;30(9):1090-1098

Excess costs of non-infectious comorbidities among people living with HIV - estimates from Denmark and Sweden.

Hjalte F; Calara PS; Blaxhult A; Helleberg M; Wallace K; Lindgren P
Article: MUSCLE & NERVE. 2018;58(3):367-373

Psychometric analysis of the pediatric quality of life inventory 3.0 neuromuscular module administered to patients with duchenne muscular dystrophy: A rasch analysis.

Landfeldt E; Mayhew A; Straub V; Lochmüller H; Bushby K; Lindgren P
Article: DIABETES-METABOLISM RESEARCH AND REVIEWS. 2018;34(4):e2984

Association between sociodemographic determinants and health outcomes in individuals with type 2 diabetes in Sweden.

Julin B; Willers C; Leksell J; Lindgren P; Looström Muth K; Svensson A-M; Lilja M; Dahlström T
Article: PLOS ONE. 2018;13(6):e0199170

Sociodemographic determinants and health outcome variation in individuals with type 1 diabetes mellitus: A register-based study.

Willers C; Iderberg H; Axelsen M; Dahlström T; Julin B; Leksell J; Lindberg A; Lindgren P; Looström Muth K; Svensson A-M; Lilja M
Article: JAMA CARDIOLOGY. 2017;2(10):1069-1078

Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.

Fonarow GC; Keech AC; Pedersen TR; Giugliano RP; Sever PS; Lindgren P; van Hout B; Villa G; Qian Y; Somaratne R; Sabatine MS
Article: HEALTH SERVICES MANAGEMENT RESEARCH. 2017;30(3):148-155

Professionals' perspectives on a market-inspired policy reform: A guiding light to the blind spots of measurement.

Korlén S; Amer-Wåhlin I; Lindgren P; von Thiele Schwarz U
Article: ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA. 2017;96(5):597-606

Case mix adjusted variation in cesarean section rate in Sweden.

Mesterton J; Ladfors L; Ekenberg Abreu A; Lindgren P; Saltvedt S; Weichselbraun M; Amer-Wåhlin I
Article: JOURNAL OF HEALTH ORGANIZATION AND MANAGEMENT. 2017;31(2):126-141

Managerial strategies to make incentives meaningful and motivating.

Korlén S; Essén A; Lindgren P; Amer-Wahlin I; von Thiele Schwarz U
Article: CLINICAL THERAPEUTICS. 2017;39(4):771-786.e3

Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain.

Villa G; Lothgren M; Kutikova L; Lindgren P; Gandra SR; Fonarow GC; Sorio F; Masana L; Bayes-Genis A; Hout BV
Article: PHARMACOECONOMICS. 2017;35(2):249-258

Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis.

Landfeldt E; Alfredsson L; Straub V; Lochmüller H; Bushby K; Lindgren P
Article: EUROPEAN JOURNAL OF CANCER. 2016;66:162-170

The cost and burden of cancer in the European Union 1995-2014.

Jönsson B; Hofmarcher T; Lindgren P; Wilking N
Article: JMIR RESEARCH PROTOCOLS. 2016;5(3):e188

A Cluster-Randomized Controlled Trial Evaluating the Effectiveness and Cost-Effectiveness of Tobacco Cessation on Prescription in Swedish Primary Health Care: A Protocol of the Motivation 2 Quit (M2Q) Study.

Leppänen A; Lindgren P; Sundberg CJ; Petzold M; Tomson T
Article: CLINICAL CARDIOLOGY. 2016;39(6):313-320

Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.

Gandra SR; Villa G; Fonarow GC; Lothgren M; Lindgren P; Somaratne R; van Hout B
Article: BMC PREGNANCY AND CHILDBIRTH. 2016;16(1):125

Case mix adjustment of health outcomes, resource use and process indicators in childbirth care: a register-based study.

Mesterton J; Lindgren P; Ekenberg Abreu A; Ladfors L; Lilja M; Saltvedt S; Amer-Wåhlin I
Article: JOURNAL OF NEUROLOGY. 2016;263(5):906-915

Quantifying the burden of caregiving in Duchenne muscular dystrophy.

Landfeldt E; Lindgren P; Bell CF; Guglieri M; Straub V; Lochmüller H; Bushby K
Article: DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY. 2016;58(5):508-515

Health-related quality of life in patients with Duchenne muscular dystrophy: a multinational, cross-sectional study.

Landfeldt E; Lindgren P; Bell CF; Guglieri M; Straub V; Lochmüller H; Bushby K
Article: NEUROMUSCULAR DISORDERS. 2015;25(12):937-944

Development and psychometric analysis of the Duchenne muscular dystrophy Functional Ability Self-Assessment Tool (DMDSAT).

Landfeldt E; Mayhew A; Eagle M; Lindgren P; Bell CF; Guglieri M; Straub V; Lochmüller H; Bushby K
Article: VALUE IN HEALTH. 2015;18(4):439-448

Determinants of Utility Based on the EuroQol Five-Dimensional Questionnaire in Patients with Chronic Heart Failure and Their Change Over Time: Results from the Swedish Heart Failure Registry.

Berg J; Lindgren P; Mejhert M; Edner M; Dahlström U; Kahan T
Article: PLOS ONE. 2015;10(11):e0140201

Time Trends in Incidence and Mortality of Acute Myocardial Infarction, and All-Cause Mortality following a Cardiovascular Prevention Program in Sweden.

Journath G; Hammar N; Elofsson S; Linnersjö A; Vikström M; Walldius G; Krakau I; Lindgren P; de Faire U; Hellénius M-L
Article: JOURNAL OF NEUROMUSCULAR DISEASES. 2015;2(1):63-72

Compliance to Care Guidelines for Duchenne Muscular Dystrophy.

Landfeldt E; Lindgren P; Bell CF; Schmitt C; Guglieri M; Straub V; Lochmüller H; Bushby K
Article: NEUROLOGY. 2014;83(6):529-536

The burden of Duchenne muscular dystrophy: an international, cross-sectional study.

Landfeldt E; Lindgren P; Bell CF; Schmitt C; Guglieri M; Straub V; Lochmüller H; Bushby K
Article: THROMBOSIS RESEARCH. 2014;133(2):162-167

Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry.

Salaj P; Kubes R; Cetkovsky P; Capova I; Penka M; Ovesná P; Mesterton J; Lindgren P
Article: JRSM CARDIOVASCULAR DISEASE. 2014;3:2048004014548735-204800401454873

Health-related quality of life and long-term morbidity and mortality in patients hospitalised with systolic heart failure.

Berg J; Lindgren P; Kahan T; Schill O; Persson H; Edner M; Mejhert M
Article: CANADIAN JOURNAL OF CARDIOLOGY. 2013;29(10):1249-1255

Cost-effectiveness of dronedarone in patients with atrial fibrillation in the ATHENA trial.

Berg J; Sauriol L; Connolly S; Lindgren P
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2013;14(3):481-493

Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation--results for Canada, Italy, Sweden and Switzerland.

Nilsson J; Åkerborg Ö; Bégo-Le Bagousse G; Rosenquist M; Lindgren P
Article: EUROPEAN JOURNAL OF INTERNAL MEDICINE. 2013;24(3):260-265

Long term health care consumption and cost expenditure in systolic heart failure.

Mejhert M; Lindgren P; Schill O; Edner M; Persson H; Kahan T
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2012;13(4):445-450

Cost-effectiveness of statins revisited: lessons learned about the value of innovation.

Lindgren P; Jönsson B
Article: CLINICAL THERAPEUTICS. 2012;34(8):1788-1802

Cost-effectiveness of dronedarone in atrial fibrillation: results for Canada, Italy, Sweden, and Switzerland.

Åkerborg Ö; Nilsson J; Bascle S; Lindgren P; Reynolds M
Article: PHARMACOECONOMICS. 2012;30(6):513-530

Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode.

Ekman M; Lindgren P; Miltenburger C; Meier G; Locklear JC; Chatterton ML
Article: THROMBOSIS RESEARCH. 2012;129(5):e233-e237

Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic.

Salaj P; Penka M; Smejkal P; Geierova V; Ovesná P; Brabec P; Cetkovsky P; Kubes R; Mesterton J; Lindgren P
Article: ACTA PSYCHIATRICA SCANDINAVICA. 2011;124(3):214-225

Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder.

Kasteng F; Eriksson J; Sennfält K; Lindgren P
Article: EUROPACE. 2011;13(1):23-30

Predictors of costs related to cardiovascular disease among patients with atrial fibrillation in five European countries.

Holstenson E; Ringborg A; Lindgren P; Coste F; Diamand F; Nieuwlaat R; Crijns H
Article: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 2010;64(9):1228-1234

The economic consequences of non-adherence to lipid-lowering therapy: results from the Anglo-Scandinavian-Cardiac Outcomes Trial.

Lindgren P; Eriksson J; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B; ASCOT trial investigators
Article: DIABETES & METABOLISM. 2010;36(3):198-203

Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetes.

Ringborg A; Lindgren P; Yin DD; Martinell M; Stålhammar J
Article: HAEMOPHILIA. 2010;16(3):487-494

The value of early treatment in patients with haemophilia and inhibitors.

Kavakli K; Yesilipek A; Antmen B; Aksu S; Balkan C; Yilmaz D; Kupesiz A; Sasmaz I; Lindgren P; Mesterton J
Article: QUALITY OF LIFE RESEARCH. 2010;19(3):381-390

Factors determining utility measured with the EQ-5D in patients with atrial fibrillation.

Berg J; Lindgren P; Nieuwlaat R; Bouin O; Crijns H
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2009;38(6):409-418

Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data.

Kobelt G; Lindgren P; Geborek P
Article: CANADIAN JOURNAL OF CARDIOLOGY. 2009;25(11):e362-e369

Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial.

Wagner M; Lindgren P; Merikle E; Goetghebeur M; Jönsson B
Article: JOURNAL OF CARDIOVASCULAR RISK. 2009;16(5):576-582

The impact of acute myocardial infarction and stroke on health care costs in patients with type 2 diabetes in Sweden.

Ringborg A; Yin DD; Martinell M; Stålhammar J; Lindgren P
Article: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 2009;63(7):997-1007

Resource use associated with type 2 diabetes in Asia, Latin America, the Middle East and Africa: results from the International Diabetes Management Practices Study (IDMPS).

Ringborg A; Cropet C; Jönsson B; Gagliardino JJ; Ramachandran A; Lindgren P
Article: ATHEROSCLEROSIS SUPPLEMENTS. 2009;10(1):3-21

Bridging science and health policy in cardiovascular disease: focus on lipid management: A Report from a Session held during the 7th International Symposium on Multiple Risk Factors in Cardiovascular Diseases: Prevention and Intervention--Health Policy, in Venice, Italy, on 25 October, 2008.

Atella V; Brady A; Catapano AL; Critchley J; Graham IM; Hobbs FDR; Leal J; Lindgren P; Vanuzzo D; Volpe M; Wood D; Paoletti R
Article: MULTIPLE SCLEROSIS JOURNAL. 2009;15(6):741-751

The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions.

Kobelt G; Texier-Richard B; Lindgren P
Article: INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE. 2009;25(2):181-189

Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.

Lindgren P; Geborek P; Kobelt G
Article: ALLERGY. 2009;64(3):431-438

An economic evaluation of NIOX MINO airway inflammation monitor in the United Kingdom.

Price D; Berg J; Lindgren P
Article: PHARMACOECONOMICS. 2009;27(3):221-230

The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1.

Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B; ASCOT investigators
Article: DIABETIC MEDICINE. 2008;25(10):1178-1186

Prevalence and incidence of Type 2 diabetes and its complications 1996-2003--estimates from a Swedish population-based study.

Ringborg A; Lindgren P; Martinell M; Yin DD; Schön S; Stålhammar J
Article: MULTIPLE SCLEROSIS JOURNAL. 2008;14(5):679-690

Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden.

Kobelt G; Berg J; Lindgren P; Jonsson B; Stawiarz L; Hillert J
Article: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 2008;62(5):708-716

Resource use and costs of type 2 diabetes in Sweden - estimates from population-based register data.

Ringborg A; Martinell M; Stålhammar J; Yin DD; Lindgren P
Article: EUROPACE. 2008;10(4):403-411

Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation.

Ringborg A; Nieuwlaat R; Lindgren P; Jönsson B; Fidan D; Maggioni AP; Lopez-Sendon J; Stepinska J; Cokkinos DV; Crijns HJGM
Article: JOURNAL OF CARDIOVASCULAR RISK. 2008;15(2):230-233

Utility loss and indirect costs after stroke in Sweden.

Lindgren P; Glader E-L; Jönsson B
Article: RESPIRATORY MEDICINE. 2008;102(2):219-231

Economic evaluation of FE(NO) measurement in diagnosis and 1-year management of asthma in Germany.

Berg J; Lindgren P
Article: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 2007;61(8):1410-1414

Determinants of cholesterol goal attainment at 12 months in patients with hypercholesterolaemia not at consensus goal after 3 months of treatment with lipid-lowering drugs.

Lindgren P; Borgström F; Stålhammar J; Alemao E; Jönsson L
Article: EUROPEAN HEART JOURNAL. 2007;28(12):1448-1453

Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.

Lindgren P; Graff J; Olsson AG; Pedersen TJ; Jönsson B; IDEAL Trial Investigators
Article: CLINICAL THERAPEUTICS. 2007;29(6):1184-1202

Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.

Berg J; Lindgren P; Spiesser J; Parry D; Jönsson B
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2007;8(1):51-57

Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany.

Brüggenjürgen B; Lindgren P; Ehlken B; Rupprecht H-J; Willich SN
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2007;8(1):25-30

Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudy.

Lindgren P; Kahan T; Poulter N; Buxton M; Svarvar P; Dahlöf B; Jonsson B; ASCOT investigators
Article: INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE. 2007;23(2):177-183

Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effective.

Lindgren P; Lindström J; Tuomilehto J; Uusitupa M; Peltonen M; Jönsson B; de Faire U; Hellénius M-L; DPS Study Group
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:5-13

Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis.

Kobelt G; Berg J; Lindgren P; Jönsson B
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:55-64

Costs and quality of life in multiple sclerosis in The Netherlands.

Kobelt G; Berg J; Lindgren P; Anten B; Ekman M; Jongen PJH; Polman C; Uitdehaag B
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:75-85

Costs and quality of life of multiple sclerosis in Sweden.

Berg J; Lindgren P; Fredrikson S; Kobelt G
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:96-104

Costs and quality of life of multiple sclerosis in the United Kingdom.

Kobelt G; Berg J; Lindgren P; Kerrigan J; Russell N; Nixon R
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:65-74

Costs and quality of life of multiple sclerosis in Spain.

Kobelt G; Berg J; Lindgren P; Izquierdo G; Sánchez-Soliño O; Pérez-Miranda J; Casado MA; Associación Española de Esclerosis Múltiple
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:14-23

Costs and quality of life of multiple sclerosis in Austria.

Kobelt G; Berg J; Lindgren P; Plesnilla C; Baumhackl U; Berger T; Kolleger H; Vass K
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:86-95

Costs and quality of life of multiple sclerosis in Switzerland.

Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:34-44

Costs and quality of life of multiple sclerosis in Germany.

Kobelt G; Berg J; Lindgren P; Elias WG; Flachenecker P; Freidel M; König N; Limmroth V; Straube E
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:45-54

Costs and quality of life of multiple sclerosis in Italy.

Kobelt G; Berg J; Lindgren P; Battaglia M; Lucioni C; Uccelli A
Article: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 2006;77(8):918-926

Costs and quality of life of patients with multiple sclerosis in Europe.

Kobelt G; Berg J; Lindgren P; Fredrikson S; Jönsson B
Article: JOURNAL OF CARDIOVASCULAR RISK. 2005;12(6):530-534

Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice.

Lindgren P; Borgström F; Stålhammar J; Alemao E; Yin DD; Jönsson L
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2005;6(4):354-362

The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial.

Ringborg A; Lindgren P; Jönsson B
Article: RHEUMATOLOGY. 2005;44(9):1169-1175

Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis.

Kobelt G; Lindgren P; Lindroth Y; Jacobson L; Eberhardt K
Article: ANNALS OF THE RHEUMATIC DISEASES. 2005;64(8):1174-1179

Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.

Kobelt G; Lindgren P; Singh A; Klareskog L
Article: EUROPEAN JOURNAL OF NEUROLOGY. 2005;12 Suppl 1:68-73

Cost of Parkinson's disease in Europe.

Lindgren P; von Campenhausen S; Spottke E; Siebert U; Dodel R
Article: JOURNAL OF CARDIOVASCULAR RISK. 2005;12(1):29-36

Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).

Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B; ASCOT investigators
Article: CLINICAL THERAPEUTICS. 2005;27(1):100-110

The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.

Lindgren P; Stenestrand U; Malmberg K; Jönsson B
Article: JOURNAL OF CARDIOVASCULAR RISK. 2004;11(6):460-465

The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study.

Lamy A; Jönsson B; Weintraub WS; Zhao F; Chrolavicius S; Bakhai A; Culler S; Gafni A; Lindgren P; Mahoney E; Yusuf S; CURE Economic Group
Article: JOURNAL OF INTERNAL MEDICINE. 2004;255(5):562-570

Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial.

Lindgren P; Jönsson B; Yusuf S
Article: PREVENTIVE MEDICINE. 2003;36(4):403-409

Cost-effectiveness of primary prevention of coronary heart disease through risk factor intervention in 60-year-old men from the county of Stockholm--a stochastic model of exercise and dietary advice.

Lindgren P; Fahlstadius P; Hellenius M-L; Jönsson B; de Faire U
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2003;4(1):37-42

The cost-effectiveness of early cabergoline treatment compared to levodopa in Sweden.

Lindgren P; Jönsson B; Duchane J
Article: ARTHRITIS & RHEUMATOLOGY. 2002;46(9):2310-2319

Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis.

Kobelt G; Jönsson L; Lindgren P; Young A; Eberhardt K
Article: PHARMACOECONOMICS. 2002;20(2):101-108

Cost-effectiveness analysis of exemestane compared with megestrol in advanced breast cancer: a model for Europe and Australia.

Lindgren P; Jönsson B; Redaelli A; Radice D
Article: PHARMACOECONOMICS. 1999;16(4):409-416

Costs of Mini Mental State Examination-related cognitive impairment.

Jönsson L; Lindgren P; Wimo A; Jönsson B; Winblad B
Article: CLINICAL THERAPEUTICS. 1999;21(7):1230-1240

The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model.

Jönsson L; Lindgren P; Wimo A; Jönsson B; Winblad B
Show more

All other publications

Letter: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2023;24(3):483

Reply to: making the rules make sense: valuation of constrained resources.

Lindgren P
Editorial comment: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2022;23(8):1259-1261

Breaking the rules: decision-making under absolute resource constraints.

Lindgren P
Editorial comment: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2021;22(6):851-854

Something borrowed, something new: measuring hospital performance in the context of value based health care.

Lindgren P; Althin R
Review: HEALTH POLICY. 2020;124(4):404-410

Risk sharing in managed entry agreements-A review of the Swedish experience.

Andersson E; Svensson J; Persson U; Lindgren P
Published conference paper: JAMA CARDIOLOGY. 2019;4(7):691-695

Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease.

Fonarow GC; van Hout B; Villa G; Arellano J; Lindgren P
Letter: ORPHANET JOURNAL OF RARE DISEASES. 2019;14(1):75

Incomplete description of the current body of evidence of the health economics of Duchenne muscular dystrophy.

Landfeldt E; Lochmüller H; Lindgren P
Letter: NEUROMUSCULAR DISORDERS. 2018;28(1):100

Compliance to care guidelines for Duchenne muscular dystrophy in Italy.

Landfeldt E; Lindgren P; Guglieri M; Lochmüller H; Bushby K
Review: JOURNAL OF NEUROMUSCULAR DISEASES. 2017;4(4):285-292

Patient Preferences for Treatments of Neuromuscular Diseases: A Systematic Literature Review.

Landfeldt E; Edström J; Lindgren P; Lochmüller H
Review: PHARMACOECONOMICS. 2017;35(3):297-318

A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies.

Wei C-Y; Quek RGW; Villa G; Gandra SR; Forbes CA; Ryder S; Armstrong N; Deshpande S; Duffy S; Kleijnen J; Lindgren P
Corrigendum: NEUROMUSCULAR DISORDERS. 2016;26(4-5):329

Corrigendum to "Development and psychometric analysis of the Duchenne muscular dystrophy Functional Ability Self-Assessment Tool (DMDSAT)" [Neuromuscular Disorders 25 (2015) 937-944].

Landfeldt E; Mayhew A; Eagle M; Lindgren P; Bell CF; Guglieri M; Straub V; Lochmüller H; Bushby K
Meeting abstract: VALUE IN HEALTH. 2014;17(7):A558

Deterministic Versus Stochastic Prediction of Risk for Cardiovascular Events.

Villa G; Lothgren M; Gandra SR; Lindgren P; van Hout B
Meeting abstract: VALUE IN HEALTH. 2010;13(3):A58

RESOURCE CONSUMPTION AND COSTS OF CARE THE YEAR BEFORE AND AFTER INITIATION OF INSULIN THERAPY IN SWEDISH PATIENTS WITH TYPE 2 DIABETES

Pettersson B; Lindgren P; Ringborg A; Martinell M; Stalhammar J
Meeting abstract: VALUE IN HEALTH. 2009;12(7):A335

DRONEDARONE IN ATRIAL FIBRILLATION: MODELING HEALTH OUTCOMES

Akerborg O; Bascle S; Lindgren P
Review: VALUE IN HEALTH. 2009;12(6):857-871

Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.

Schwander B; Gradl B; Zöllner Y; Lindgren P; Diener H-C; Lüders S; Schrader J; Villar FA; Greiner W; Jönsson B
Review: JOURNAL OF CARDIOVASCULAR RISK. 2009;16(2):138-143

From 4S to IDEAL: the health economics of the statin trials.

Lindgren P; Jönsson B
Meeting abstract: VALUE IN HEALTH. 2008;11(6):A548

COST-EFFECTIVENESS OF RITUXIMAB AS SECOND-LINE BIOLOGICAL TREATMENT COMPARED TO REGISTRY DATA

Kobelt G; Lindgren P
Meeting abstract: VALUE IN HEALTH. 2008;11(6):A410

FACTORS DETERMINING UTILITY MEASURED WITH THE EQ-5D IN PATIENTS WITH ATRIAL FIBRILLATION

Berg J; Lindgren P; Nieuwlaat R; Bascle S; Crijns H
Published conference paper: CURRENT MEDICAL RESEARCH AND OPINION. 2008;24(7):2089-2101

Cost-effectiveness of clopidogrel treatment in percutaneous coronary intervention: a European model based on a meta-analysis of the PCI-CURE, CREDO and PCI-CLARITY trials.

Berg J; Fidan D; Lindgren P
Editorial comment: HEART. 2008;94(2):e4

Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.

Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B; ASCOT trial investigators
Corrigendum: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2007;8(4):359

Costs and quality of life in multiple sclerosis in The Netherlands (vol 7, pg S55, 2006)

Kobelt G; Berg J; Lindgren P; Anten B; Ekman M; Jongen PJH; Polman C; Uitdehaag B
Meeting abstract: ATHEROSCLEROSIS SUPPLEMENTS. 2007;8(1):197-198

Trial based economic evaluation of intensive atorvastatin compared to standard simvastatin in the IDEAL trial

Lindgren P; Jonsson B
Review: EUROPEAN HEART JOURNAL SUPPLEMENTS. 2007;9(C):c3-c74

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases:: full text

Ryden L; Standl E; Bartnik M; Van den Berghe G; Betteridge J; de Boer M-J; Cosentino F; Jonsson B; Laakso M; Malmberg K; Priori S; Ostergren J; Tuomilehto J; Thrainsdottir I; Vanhorebeek I; Stramba-Badiale M; Lindgren P; Qiao Q; Priori SG; Blanc J-J; Budaj A; Camm J; Dean V; Deckers J; Dickstein K; Lekakis J; McGregor K; Metra M; Morais J; Osterspey A; Tamargo J; Luis Zamorano J; Deckers JW; Bertrand M; Charbonnel B; Erdmann E; Ferrannini E; Flyvbjerg A; GohIke H; Gonzalez Juanatey JR; Graham I; Monteiro PF; Parhofer K; Pyorala K; Raz I; Schernthaner G; Volpe M; Wood D
Meeting abstract: VALUE IN HEALTH. 2007;10(3):A64

Determination of health care costs incurred by swedish patients with type 2 diabetes

Ringborg A; Stalhammar J; Martinell D; Lindgren P
Meeting abstract: VALUE IN HEALTH. 2007;10(3):A110

Economic evaluation of a new airway inflammation monitor in the diagnosis and management of asthma in the US

Berg J; Lindgren P
Review: EUROPEAN HEART JOURNAL. 2007;28(1):88-136

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD).

Rydén L; Standl E; Bartnik M; Van den Berghe G; Betteridge J; de Boer M-J; Cosentino F; Jönsson B; Laakso M; Malmberg K; Priori S; Ostergren J; Tuomilehto J; Thrainsdottir I; Vanhorebeek I; Stramba-Badiale M; Lindgren P; Qiao Q; Priori SG; Blanc J-J; Budaj A; Camm J; Dean V; Deckers J; Dickstein K; Lekakis J; McGregor K; Metra M; Morais J; Osterspey A; Tamargo J; Zamorano JL; Deckers JW; Bertrand M; Charbonnel B; Erdmann E; Ferrannini E; Flyvbjerg A; Gohlke H; Juanatey JRG; Graham I; Monteiro PF; Parhofer K; Pyörälä K; Raz I; Schernthaner G; Volpe M; Wood D; Task Force on Diabetes and Cardiovascular Diseases; European Association for the Study of Diabetes (EA
Meeting abstract: VALUE IN HEALTH. 2006;9(6):A353

Cost-utility analysis of eprosartan compared to enalapril and ramipril in the treatment of moderate to severe hypertension in Sweden

Lindgren P; Schwander B; Zollner Y; Jonsson B
Meeting abstract: VALUE IN HEALTH. 2006;9(6):A346-A347

Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation:: European model results based on clarity and commit

Berg J; Lindgren P; Jonsson B
Meeting abstract: VALUE IN HEALTH. 2006;9(6):A333

Economic evaluation of a new airway inflammation monitor in the diagnosis and management of asthma in Germany

Berg J; Lindgren P; Joensson B
Meeting abstract: VALUE IN HEALTH. 2006;9(6):A330

Utility loss and indirect costs after stroke in Sweden

Lindgren P; Glader EL; Jonsson B
Meeting abstract: VALUE IN HEALTH. 2006;9(6):A231-A232

Cost of inpatient and outpatient care of Swedish patients with diabetes mellitus

Ringborg A; Berwick S; Stalhammar J; Martinell M; Lindgren P
Meeting abstract: VALUE IN HEALTH. 2006;9(6):A231

Cost of a major hypoglycaemic event in type 1 and type 2 diabetic patients - A systematic literature review

Lilja U; Asmussen M; Lindgren P
Meeting abstract: ATHEROSCLEROSIS SUPPLEMENTS. 2006;7(3):178

Trial based economic evaluation of intensive atorvastatin compared to standard simvastatin in the ideal trial

Lindgren P; Jonsson B
Meeting abstract: VALUE IN HEALTH. 2005;8(6):A134

The cost of multiple sclerosis (MS) in Europe

Berg J; Kobelt G; Lindgren P; Fredrikson S; Jönsson B
Meeting abstract: VALUE IN HEALTH. 2005;8(3):253

9301 cost-effectiveness of long-term therapy with clopidogrel following percutaneous coronary intervention:: A Swedish analysis of the CREDO-trial

Ringborg A; Lindgren P; Jönsson B
Meeting abstract: VALUE IN HEALTH. 2004;7(6):694

Cost-effectiveness of reduction in cardiovascular outcomes with atorvastatin in patients with normal to mildly elevated cholesterol levels, treated for hypertension:: The ASCOT-LLA study

Lindgren P; Buxton MJ; Kahan T; Poulter N; Dahlöf B; Sever P; Wedel H; Jönsson B
Meeting abstract: VALUE IN HEALTH. 2004;7(6):688

The cost-effectiveness of clopidogrel in patients undergoing percutaneous coronary intervention in Sweden:: An analysis of PCI-cure

Lindgren P; Stenestrand U; Malmberg K; Jönsson B
Review: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2004;5 Suppl 1:S63-S66

Economic evidence in Parkinson's disease: a review.

Lindgren P
Meeting abstract: VALUE IN HEALTH. 2003;6(6):621

Short and long term cost-effectiveness analysis of clopidogrel in patients with acute coronary syndrome without ST segment elevation (ACS) in Scandinavian countries

Lindgren P; Jönsson B; Spiesser J; Carita P; Gabriel S
Meeting abstract: EUROPEAN HEART JOURNAL. 2003;24:586

Cost-effectiveness analysis of clopidogrel in acute coronary syndromes without ST-segment elevation: a five European countries analysis

Annemans L; Lindgren P; Frei A; Gabriel S; Carita P
Meeting abstract: EUROPEAN HEART JOURNAL. 2003;24:245

Cost-effectiveness analysis of clopidogrel in patients with unstable coronary artery disease undergoing percutaneous coronary interventions: a five European countries analysis

Annemans L; Lindgren P; Frei A; Gabriel S; Spiesser J
Show more

Employments

Adjunct Professor, Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, 2021-2025

Degrees and Education

Docent, Karolinska Institutet, 2014
Doctor Of Philosophy, Institute of Environmental Medicine, Karolinska Institutet, 2005

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI